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ABSTRACT
Background. Conditional survival is the survival proba-
bility after already surviving a predefined time period. This
may be informative during follow-up, especially when
adjusted for tumor characteristics. Such prediction models
for patients with resected pancreatic cancer are lacking and
therefore conditional survival was assessed and a nomo-
gram predicting 5-year survival at a predefined period after
resection of pancreatic cancer was developed.
Methods. This population-based study included patients
with resected pancreatic ductal adenocarcinoma from the
Netherlands Cancer Registry (2005–2016). Conditional
survival was calculated as the median, and the probability
of surviving up to 8 years in patients who already survived
0–5 years after resection was calculated using the Kaplan–
Meier method. A prediction model was constructed.
Results. Overall, 3082 patients were included, with a
median age of 67 years. Median overall survival was
18 months (95% confidence interval 17–18 months), with a
5-year survival of 15%. The 1-year conditional survival
(i.e. probability of surviving the next year) increased from
55 to 74 to 86% at 1, 3, and 5 years after surgery,
respectively, while the median overall survival increased
from 15 to 40 to 64 months at 1, 3, and 5 years after sur-
gery, respectively. The prediction model demonstrated that
the probability of achieving 5-year survival at 1 year after
surgery varied from 1 to 58% depending on patient and
tumor characteristics.
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Conclusions. This population-based study showed that
1-year conditional survival was 55% 1 year after resection
and 74% 3 years after resection in patients with pancreatic
cancer. The prediction model is available via www.pancrea
scalculator.com to inform patients and caregivers.
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Pancreatic ductal adenocarcinoma (hereafter called
pancreatic cancer) is one of the most lethal cancers. In
Europe and the US, approximately 18 per 100,000 persons
and 13 per 100,000 persons, respectively, are diagnosed
with this disease annually.1,2 Approximately 16% of all
patients will undergo surgical resection, with a 5-year
survival rate of 15–20%.3–5 Survival following resection of
pancreatic cancer has improved because of better adjuvant
treatment strategies.6,7 Therefore, increasing numbers of
patients with pancreatic cancer will survive the first year
following surgery and these patients might want to be
informed about accurate data on survival estimates during
follow-up.
Survival estimates are traditionally calculated from the
time of diagnosis or from the time of surgery. However, in
patients who underwent pancreatic resection for pancreatic
cancer, predicted survival changes considerably during
follow-up.8–10 Conditional survival (CS), defined as the
survival probability and calculated in the subgroup of
patients who have survived a predefined period, may
therefore provide better insight. This could for instance be
relevant when patients in follow-up after resection of
pancreatic cancer are faced with important decisions
regarding work and personal life, with impact on both
themselves and their next of kin. CS may also facilitate
appropriate risk stratification of patients, e.g. regarding the
frequency and timing of follow-up.8–13 For optimal risk
stratification, calculation of the CS probability should also
take other predictors of overall survival into account.
Multiple prediction models have been developed for sur-
vival after surgery for pancreatic cancer;14,15 however,
prediction models for CS in pancreatic cancer are lacking.
The Netherlands Cancer Registry (NCR) contains
patient, tumor, and treatment characteristics of all patients
with pancreatic cancer, as well as corresponding survival
data. The objective of this study was to assess CS using
nationwide NCR data for patients who underwent resection
of pancreatic cancer and to develop a nomogram to predict
CS probabilities, with the possibility of adjusting survival
estimates for a certain period already survived after
surgery.
METHODS
Study Design
This cohort study used nationwide data from the NCR, a
prospective population-based database that covers all
Dutch hospitals (i.e. a population of 16.8 million). Infor-
mation on patient, tumor, and treatment characteristics
from patients with a newly diagnosed malignancy are
routinely collected from medical records by trained NCR
administrators. Patients were queried from the national
pathological archive (PALGA) and the National Registry
of Hospital Discharge Diagnoses. This study was reported
in accordance with the STROBE guidelines.16 No informed
consent was required as anonymized data were used.
Study Population
Patients who underwent resection of pancreatic ductal
adenocarcinoma during the period 2005–2016 were
extracted from the NCR database (International Classifi-
cation of Diseases for Oncology, Third Revision [ICD-O-3]
morphology codes are shown in electronic supplementary
Text 1). Pancreatic resection was defined as pancreato-
duodenectomy, distal pancreatectomy, or total
pancreatectomy. Patients younger than 18 years of age at
the time of diagnosis, patients with neuroendocrine tumors,
and patients with distant metastases were excluded. In
addition, patients, who died within 30 days after surgery
were excluded since our aim was to develop a nomogram
for postoperative use in the outpatient clinic.
Data Collection
Primary tumor location was classified as the pancreatic
head, body, tail, or other/not otherwise specified (NOS),
according to the ICD-O-3. Staging was based on patho-
logical classification according to the TNM classification at
the time of registration (6th edition of the Union for
International Cancer Control [UICC] TNM staging during
2005–2009; 7th edition of the UICC TNM staging during
2010–2016).17,18 In case of neoadjuvant treatment or
missing pathological TNM stage, the clinical TNM clas-
sification was used. Adjuvant chemotherapy has been
recommended since 2008 after judgment of a national
commission (Commissie BOM), and was, according to the
guidelines, almost universally gemcitabine only. Survival
data were obtained by an annual cross-check with the
Municipal Personal Records Database, which contains the
vital status of all Dutch inhabitants. Survival was calcu-
lated as the time between the date of surgery (or date of
histological diagnosis when the date of surgery was
unknown, n = 3) and date of death, or censored when alive
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at the last check of the patient’s vital status (1 February
2018).
Statistical Analysis
Patient, tumor, and treatment characteristics were pre-
sented using descriptive statistics. Overall survival was
calculated using the Kaplan–Meier method. CS was
defined as the probability of surviving an additional num-
ber of ‘y’ years, given that a patient had already survived
for ‘x’ years, and was calculated as CS(x|y) = S(x?y)/S(x),
with S(x) representing the overall survival at x years esti-
mated using the Kaplan–Meier method.12 For example, to
estimate the CS for surviving 2 more years for patients who
had already have survived 3 years after surgery, CS(3|2) is
calculated by dividing the 5-year Kaplan–Meier survival
estimate S(5) by the 3-year Kaplan–Meier survival estimate
S(3).
8,19–21 Median CS was also determined at specific
times and was derived from Kaplan–Meier estimates by
discarding the patients who died before that time.
To develop a nomogram predicting 5-year survival, the
predictors of the previously published and externally vali-
dated Amsterdam model were used.14,22 This model was
used because of its simplicity and methodological quality
according to a recent systematic review and to maintain
consistency with previous studies.14,23 The Amsterdam
model uses adjuvant chemotherapy, margin status, tumor
differentiation, and lymph node ratio to predict overall
survival for patients who underwent pancreatoduodenec-
tomy for pancreatic cancer.14 Moreover, age was also
incorporated in the prediction model because of its relation
with CS. In the current study, multiple imputation was used
to impute missing data by creating 10 datasets, using the
mice package in R. Variables of the Amsterdam model
were included in a multivariable Cox proportional hazards
model. A penalized LASSO model (Least Absolute
Shrinkage and Selector Operator) was used in order to
enhance prediction accuracy and reduce overfitting.24
Results were presented as hazard ratios (HR) with 95%
confidence intervals (CIs). A nomogram was created and
the C-statistic was presented, with optimism adjusted for
by bootstrapping (B = 200). Nomogram-predicted CS rates
to reach 5-year survival were presented directly after sur-
gery and given 1, 2, 3, and 4 years survival after surgery
(for use in the outpatient clinic during follow-up). Of note,
CS predictions ‘directly after surgery’ are actually the
predictions at 30 days post-surgery (since 30-day mortality
was excluded), but was described as ‘directly after surgery’
to enhance readability. All p values were based on a two-
sided test and p values\ 0.05 were considered statistically
significant. Statistical analysis was performed using IBM
SPSS Statistics for Windows version 25 (IBM Corporation,
Armonk, NY, USA) and R version 3.4.3 (cran.r-
project.org).
RESULTS
In total, 3204 patients underwent resection of pancreatic
cancer between 2005 and 2016. Patients who died within
30 days after surgery were excluded (4%, n = 122). The
final cohort consisted of 3082 patients; median age was
67 years (interquartile range 60–73) and 1630 patients
(53%) were male. All baseline characteristics are shown in
Table 1.
Overall and Conditional Survival
Median overall survival was 18 months (95% CI
17–18 months), with a 5-year survival of 15% (Fig. 1). The
survival probability increased per year already survived
relative to the total survival time. The probability of
achieving 5-year survival after resection increased from
15% directly after surgery to 23%, 42%, 61%, and 82% per
additional year survived (i.e. 1, 2, 3, and 4 years after
resection, respectively). The 1-year CS (i.e. probability of
surviving the next year) decreased from 67% directly after
surgery to 55% at 1 year after surgery, and then increased
to 74% and 86% at 3 and 5 years after surgery, respectively
(Fig. 1). The median CS decreased from 18 months (95%
CI 17–18) directly after surgery to 15 months (95% CI
14–16) at 1 year after surgery, and then increased to 40
(95% CI 32–52) and 64 months (95% CI 54—not reached)
at 3 and 5 years after surgery, respectively.
Multivariable Analysis of Survival
In our cohort, all four variables of the Amsterdam model
(i.e. adjuvant chemotherapy, margin status, tumor differ-
entiation, and lymph node ratio), as well as age, were
independent predictors of survival in a multivariable Cox
analysis (Table 2). Moderately and poorly differentiated
tumors were associated with worse survival compared with
well-differentiated tumors (HR 1.27 [95% CI 1.11–1.46]
for moderately differentiated tumors, and HR 1.74 [95% CI
1.51–2.00] for poorly/undifferentiated tumors). In addition,
higher lymph node ratio and an R1/R2 resection margin
were independently associated with decreased survival, as
was the absence of use of adjuvant chemotherapy (HR 1.64
[95% CI 1.51–1.79]).
Prediction Nomogram for Conditional Survival
In Fig. 2, a nomogram was created based on the pre-
dictors of the multivariable Cox model. The prediction
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model had a calibration slope of 1.1 (electronic supple-
mentary Fig. 1) and an optimism-adjusted C-statistic of
0.65 (95% CI 0.64–0.66). The nomogram predicts the
probability of reaching 5-year survival directly after sur-
gery and after surviving 1–4 years after surgery. Quartiles
of the nomogram score are indicated in the nomogram to
show the distribution of the current cohort. The probability
of achieving 5-year survival, measured 1 year after sur-
gery, varied from 1 to 58% depending on patient and tumor
characteristics. For example, a 60-year-old patient with a
moderately differentiated tumor and a lymph node ratio of
\ 0.18 who underwent an R1 resection without adjuvant
chemotherapy would have a total nomogram score of 249
(24 ? 37 ? 58 ? 55 ? 75). The probability of being
alive 5 years after surgery was 10% after surviving the first
year for this particular patient, CS(5|1), increasing to 45%
when surviving the first 3 years after surgery, CS(5|3). If this
patient had received adjuvant chemotherapy, the total
nomogram score would have been 174 points
(24 ? 37 ? 58 ? 55) and the probability of 5-year sur-
vival would have been 25% after surviving the first year,
rising to 61% after surviving the first 3 years after surgery,
CS(5|3).
A calculator to estimate the probability of achieving
5-year survival, calculated from the time of surgery, given
‘x’ years of survival after surgery, has been made available
at www.pancreascalculator.com.
DISCUSSION
This nationwide study in 3082 patients who underwent
resection of pancreatic cancer is the first to present a pre-
diction model for CS. The probability of achieving 5-year
survival after pancreatic resection increased from 15%
directly after surgery to 61% after surviving the first
3 years. A prediction model was created, using easily
accessible predictors, and has been made available at www.
pancreascalculator.com to estimate patient-specific CS
probabilities for 5-year survival after surgery.
CS is especially of interest in cancers with a poor sur-
vival prognosis as the survival estimates change
considerably after surviving the first year. In the current
study, the 1-year CS (i.e. the probability of surviving
another year) decreased the first year after surgery (67%
directly after surgery vs. 55% at 1 year after surgery). This
indicates that relatively more patients die in the second
year after surgery than in the first year after surgery. After
this initial decrease, the 1-year CS estimates gradually
increase. The large decline in survival in the second year
after surgery is merely a reflection of the non-linear death
rate in patients diagnosed with pancreatic cancer. In other
large series, disease recurrence also typically occurs after a
median of 12 months.25 Patients who have survived the
first years after surgery probably have less aggressive
cancers. This is also confirmed by the different shapes of
TABLE 1 Baseline characteristics of 3082 patients with resected
pancreatic cancer diagnosed between 2005 and 2016
Clinicopathological parameters Total cohorta [n = 3082]
Male 1630 (53)
Age, years [median (IQR)] 67 (60–73)
\ 70 1892 (61)
C 70 1190 (39)
Primary tumor location
Head of the pancreas 2509 (81)
Corpus of the pancreas 110 (3.6)
Tail of the pancreas 235 (7.6)
Pancreas, NOS 228 (7.4)
Type of operation
Pancreatoduodenectomy 2686 (87)
Distal pancreatectomy 333 (11)
Total pancreatectomy 47 (1.5)
Other/NOS 16 (0.5)
Tumor differentiation grade
Well-differentiated (grade I) 360 (12)
Moderately differentiated (grade II) 1626 (53)
Poorly or undifferentiated (grade III) 1096 (36)
Missing 484 (16)
Pathological T stageb
T1 222 (7.2)
T2 555 (18)
T3 2167 (70)
T4 138 (4.5)
Pathological N stagec
N0 1000 (32)
N1 2082 (68)
Resection margin status
R0 2065 (67)
R1 966 (31)
R2 51 (1.6)
Missing 132 (4.3)
Neoadjuvant chemo(radio)therapy 140 (4.5)
Adjuvant chemotherapy 1492 (48)
Data are expressed as n (%) unless otherwise stated
IQR interquartile range, NOS not otherwise specified
aImputed data are presented. Percentages are separately calculated for
the group of missing values, explaining the cumulative exceeding
100% for tumor grade and resection margin status
bClinical T stage was used in case of missing pathological T stage
(n = 26, 0.8%)
cClinical N stage was used in case of missing pathological N stage
(n = 49, 1.6%)
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the CS curves in Fig. 1 (the concave becoming more linear
over time). Another explanation might be extensive patient
care with optimization of the physical condition perioper-
atively and during the first year postoperatively. After the
first year, oncological treatments are typically completed
and the intensity of supportive care potentially decreases.
However, the exact reason of the biggest decline in the
second year after surgery remains unknown.
The increase in the CS after these first years is probably
because only patients who had a tumor with favorable
biological behavior remain. These patients survive until
late tumor recurrence or other causes of death, leading to
an increased CS as patients have accrued a longer post-
operative survival. Moreover, distinction between
pancreatic, ampullary and distal bile duct cancer remains
challenging, while these cancers carry different prog-
noses.26 Tumors might be misclassified as pancreatic
ductal adenocarcinoma and patients could therefore have a
better survival than expected, being translated in increasing
CS over time.
The survival in this study is lower compared with other
large, monocenter series;27,28 however, this is a population-
based study and the results are therefore more representa-
tive than studies with selected cohorts, for example from
single, high-volume centers. Compared with the popula-
tion-based Surveillance, Epidemiology, and End Results
(SEER) database, our results are similar.29
The current CS estimates are developed for the outpa-
tient clinic after full recovery from surgery and when
patients would like to discuss their prognosis and future
perspectives. Our nomogram uses readily available and
widely recognized predictors of survival in pancreatic
cancer. Although some might argue that a C-statistic of
0.65 is relatively low, it is in line with previous prediction
models in pancreatic cancer.23 The difficulty in accurately
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Total Points
0 50 100 150 200 250 300 350 400
Probability of 5−year survival
Directly after surgery 0.010.050.10.20.30.40.50.6
Probability of 5−year survival
Given 1 year survival after surgery 0.010.050.10.20.30.40.50.6
Probability of 5−year survival
Given 2 year survival after surgery 0.050.10.20.30.40.50.60.7
Probability of 5−year survival
Given 3 year survival after surgery 0.20.30.40.50.60.70.8
Probability of 5−year survival
Given 4 year survival after surgery 0.50.60.70.80.9
Q1 Q2 Q3 Q4
FIG. 2 Nomogram for the
prediction of overall and
conditional survival to achieve
5-year survival after
resection. For a given patient
per variable of the nomogram,
locate the corresponding value
and draw a vertical line upward
toward the ‘Points’ axis. Add
the points for all four variables
and draw a vertical line from
this number of points from the
‘Total Points’ axis downwards
through the probability axes.
This will indicate the patient’s
probability to reach 5-year
survival directly after surgery
and 1, 2, 3, and 4 years after
surgery
TABLE 2 Univariable and multivariable Cox regression analyses according to the Amsterdam model in patients with resected pancreatic cancer
diagnosed between 2005 and 2016
Clinicopathological parameter Median OS, months 5-year survival (%) Univariable analysis
HR (95% CI)
Multivariable analysis
HR (95% CI)b
p valuec
Age (each incremental year) – – 1.01 (1.00–1.01) 1.00 (1.00–1.01) 0.04
Tumor differentiation grade
Well-differentiated 27 27 1.00 (reference) 1.00 (reference)
Moderately differentiated 19 16 1.41 (1.21–1.65) 1.27 (1.11–1.46) 0.001
Poorly or undifferentiated 14 12 1.94 (1.66–2.28) 1.74 (1.51–2.00) \ 0.001
Lymph node ratioa
0 (lymph node-negative) 25 28 1.00 reference 1.00 (reference)
[ 0 and B 0.18 18 13 1.44 (1.27–1.63) 1.47 (1.31–1.64) \ 0.001
[ 0.18 15 8 1.86 (1.67–2.07) 1.94 (1.76–2.14) \ 0.001
Resection margin
R0 20 19 1.00 (reference) 1.00 (reference)
R1/R2 14 8 1.57 (1.44–1.70) 1.44 (1.33–1.57) \ 0.001
Adjuvant chemotherapy
Yes 21 20 1.00 (reference) 1.00 (reference)
No 14 11 1.52 (1.41–1.65) 1.64 (1.51–1.79) \ 0.001
Data after multiple imputation were used
OS overall survival, HR hazard ratio, CI confidence interval
aLymph node ratio is the number of positive lymph nodes divided by the total number of lymph nodes harvested
bHazard ratios and 95% CIs from the Cox LASSO model are presented
cp values of multivariable analyses are shown
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predicting survival after resected pancreatic cancer is partly
related to the narrow-banded survival distribution (poor
prognosis for the vast majority of patients with very few
long-term survivors), which complicates accurate dis-
crimination in terms of clinical outcome.
Recently, other studies reported on CS in colorectal liver
metastases, hepatocellular carcinoma, non-small lung
cancer, and malignant brain tumors.20,21,30,31 However, in
pancreatic cancer, only a few, mostly single-center studies
have assessed CS without taking other prognostic factors
into account.8–11,13,32,33 One European study analyzed CS
among all stages of pancreatic cancer, stratified for age and
sex, but presented only limited information on CS.32
Another recent study combined data from Verona and
Boston and stratified for TNM stage, tumor grade, resection
margin, and adjuvant therapy.33 This study separated
patients with and without tumor recurrence. Unfortunately,
this was not possible in our cohort since this information
was not yet available in the NCR during 2005–2016.
Comparison of the overall population analysis from that
study with our results showed that 1-year CS was slightly
higher in their study, but this effect diminished over time.33
Moreover, a recent study including five national cancer
registries developed a survival-predicting model for 1-, 2-,
3-, and 5-year survival probabilities.34 CS was not calcu-
lated in this large cohort. However, none of the previously
mentioned series proposed a way to calculate CS with
adjustment for known clinicopathological predictors. As
known from previous studies, not only time since resection
affected overall survival but obviously also patient, tumor,
and treatment characteristics.27,35,36 In studies on CS for
gastric cancer, a nomogram to adjust for covariates was
created and consequently increased the accuracy of CS
estimates.37,38
Patients might be unable to adequately interpret tradi-
tional 3- and 5-year survival estimates, potentially leading
to rigorous decisions. The nomogram created in the current
study will potentially add to traditional survival estimates
in counselling patients and surveillance during follow-up.
Moreover, patients prefer explicit information about
prognosis.39 Some patients might experience anxiety as
3 years after surgery is approaching, while this study
demonstrates that CS rates are actually improving over
time. These psychological consequences, such as fear of
cancer recurrence or death, become more important due to
novel and improved treatment possibilities that increase
survival.40 Personalized survival estimates will potentially
aid to deal with these psychological factors and will pave
the way for personalized follow-up schedules. Further-
more, as can be calculated with the prediction model,
patients with adjuvant chemotherapy have higher CS esti-
mates compared with patients without chemotherapy.
These estimates might increase the patients’ visualization
of the impact of adjuvant chemotherapy on survival. Based
on these estimates, one might also cautiously advocate for
the treatment of oligometastatic disease after 2–3 years
progression-free survival as CS probabilities are improving
over time.
This study has some limitations. First, the retrospective
design could have caused bias because surgical and
pathological procedures were not standardized among
centers. For example, the pathological assessment of pan-
creatic resection specimens improved considerably during
these years (2005–2016), which we were not able to adjust
for retrospectively and might have influenced our results.
Second, one of the strengths of this study, the long study
period, also represents one of its limitations. Surgical
outcomes improved due to increased centralization, and
new (neo)adjuvant chemotherapy regimens were intro-
duced.6, 41–44 It is likely that the majority of patients
received adjuvant gemcitabine monotherapy, whereas now
most patients receive (neo)adjuvant FOLFIRINOX,
resulting in an improved survival.6 Unfortunately, in our
cohort, only a small proportion of patients was treated
neoadjuvantly as this was only done in randomized trials
during these years. With new insights available and treat-
ment shifting rapidly towards neoadjuvant therapy, the
current CS estimates are probably an underestimation of
the actual prognosis. An update of the nomogram would be
appropriate in a few years due to these improvements,
perhaps including the type of chemotherapy and com-
pleteness of chemotherapy regimens. Third, no data were
available on tumor recurrence and cancer antigen (CA)
19-9. Recurrence has a considerable prognostic impact, as
was shown in the study from Verona and Boston.33 The
NCR database is currently expanded with recurrence data,
and, subsequently, further research should incorporate
these data to improve patient-tailored calculations. CA19-9
is a tumor marker that was shown to be of prognostic value
but was not yet registered in a considerable proportion of
the patients included in our cohort and could therefore not
be considered in our analysis.26 Fourth, it should be noted
that the number of patients at risk in the CS analysis sub-
stantially decreased over time. Smaller groups obviously
result in wider CIs, especially longer after surgery, which
should be taken into account. Due to the statistical chal-
lenges to calculate CIs of the CS Kaplan–Meier estimates,
the number of patients at risk is presented instead.
CONCLUSION
This nationwide study describes CS following resection
of pancreatic cancer. A nomogram and online calculator
based on national data may be useful for counselling
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patients during follow-up. External validation of the
nomogram and CS estimates in other cohorts of patients
with pancreatic cancer would be recommended.
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